血浆磷酸化tau与奈弗拉帕莫治疗路易体痴呆患者疗效的相关性
AscenD-LB 2a期随机安慰剂对照试验的事后分析显示,在85例轻中度路易体痴呆患者中,基线血浆ptau181低于2.2 pg/mL者(45例)接受奈弗拉帕莫40 mg每日三次治疗16周后,多项终点较安慰剂显著改善;高于该阈值者(40例)改善幅度较小。作者认为,排除血浆ptau181升高患者可富集对奈弗拉帕莫更敏感的路易体痴呆人群,并建议将阿尔茨海默病共病血浆生物标志物作为路易体痴呆临床试验的分层变量。
要点
- 基线血浆ptau181低于2.2 pg/mL的亚组中,奈弗拉帕莫40 mg每日三次较安慰剂显著改善注意力复合评分等多项终点。
- 基线血浆ptau181高于2.2 pg/mL的亚组中,奈弗拉帕莫的改善幅度小于低于阈值亚组。
- 作者认为,排除血浆ptau181升高患者可富集对奈弗拉帕莫更敏感的路易体痴呆人群。
核心结论
- 排除血浆ptau181升高的患者,可能通过排除广泛皮层神经变性患者,富集对奈弗拉帕莫更敏感的路易体痴呆人群。
- 研究入口时阿尔茨海默病共病的血浆生物标志物应作为路易体痴呆临床试验的分层变量。
研究设计与样本
- AscenD-LB研究为2a期、随机(1:1)、16周、安慰剂对照临床试验,主要结果已发表。
- 研究完成后(事后)测定治疗前血浆ptau181水平,以2.2 pg/mL为阿尔茨海默病病理阈值(在另一队列中建立以区分阿尔茨海默病与健康对照)将85例轻中度路易体痴呆患者分组:45例低于阈值、40例高于阈值。
- 在每一亚组内(基线血浆ptau181低于和高于2.2 pg/mL)采用混合模型重复测量分析,比较安慰剂与奈弗拉帕莫40 mg每日三次(所研究的2个剂量中较高且临床活性更强的剂量)的临床结局。
主要发现
- 在16周治疗期内,比较安慰剂与奈弗拉帕莫40 mg每日三次,所有评估终点中,低于阈值者的奈弗拉帕莫治疗改善均大于高于阈值者。
- 基线血浆ptau181低于阈值者中,奈弗拉帕莫较安慰剂在注意力复合评分上显著改善(+0.42,95%CI 0.07-0.78,p=0.023,d=0.78)。
- 基线血浆ptau181低于阈值者中,奈弗拉帕莫较安慰剂在临床痴呆评定量表总和箱评分上显著改善(-0.60,95%CI -1.04至-0.06,p=0.031,d=0.70)。
- 基线血浆ptau181低于阈值者中,奈弗拉帕莫较安慰剂在计时起立行走试验上显著改善(-3.1秒,95%CI -4.7至-1.6,p<0.001,d=0.74)。
- 基线血浆ptau181低于阈值者中,奈弗拉帕莫较安慰剂在国际购物清单测验-再认上显著改善(+1.4,95%CI 0.2-2.5,p=0.024,d=1.00)。
关键数值与推荐
- 阿尔茨海默病病理的血浆ptau181阈值为2.2 pg/mL,该阈值在另一队列中建立以区分阿尔茨海默病与健康对照。
- 奈弗拉帕莫剂量为40 mg每日三次(所研究的2个剂量中较高且临床活性更强的剂量)。
临床怎么用
- 作者认为,排除血浆ptau181升高的患者可富集对奈弗拉帕莫更敏感的路易体痴呆人群。
- 作者认为,研究入口时阿尔茨海默病共病的血浆生物标志物应作为路易体痴呆临床试验的分层变量。
局限性
- 血浆ptau181水平在主要研究完成后测定,数据按事后分析处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In a proportion of patients, dementia with Lewy bodies (DLB) is associated with Alzheimer disease (AD) copathology, which is linked to accelerated cognitive decline and more extensive cortical atrophy. The objective was to evaluate the relationship between a biomarker of AD copathology, plasma tau phosphorylated at residue 181 (ptau181), and the treatment effects of the p38α kinase inhibitor neflamapimod, which targets the cholinergic degenerative process in DLB. METHODS: The AscenD-LB study was a phase 2a, randomized (1:1), 16-week, placebo-controlled clinical trial of neflamapimod in DLB, the main results of which have been published. After the study was completed (i.e., post hoc), pretreatment plasma ptau181 levels were determined and participants were grouped based on a cutoff for AD pathology of 2.2 pg/mL (established in a separate cohort to identify AD from healthy controls). Clinical outcomes for the comparison of placebo with neflamapimod 40 mg three times daily (TID; the higher and more clinically active of 2 doses studied) were analyzed using mixed models for repeated measures within each subgroup (baseline plasma ptau181 < and ≥2.2 pg/mL). RESULTS: Pretreatment plasma ptau181 levels were determined in eighty-five participants with mild-to-moderate DLB receiving cholinesterase inhibitors, with 45 participants below and 40 above the 2.2 pg/mL cutoff at baseline. In the 16-week treatment period, in the comparison of placebo with neflamapimod 40 mg TID, for all end points evaluated, improvements with neflamapimod treatment were greater in participants below the cutoff, compared with those above the cutoff. In addition, participants below the ptau181 cutoff at baseline showed significant improvement over placebo in an attention composite measure (+0.42, 95% CI 0.07-0.78, p = 0.023, d = 0.78), the Clinical Dementia Rating Scale Sum of Boxes (-0.60, 95% CI -1.04 to -0.06, p = 0.031, d = 0.70), the Timed Up and Go test (-3.1 seconds, 95% CI -4.7 to -1.6, p < 0.001, d = 0.74), and International Shopping List Test-Recognition (+1.4, 95% CI 0.2-2.5, p = 0.024, d = 1.00). DISCUSSION: Exclusion of patients with elevated plasma ptau181, potentially through excluding patients with extensive cortical neurodegeneration, enriches for a patient with DLB population that is more responsive to neflamapimod. More generally, plasma biomarkers of AD copathology at study entry should be considered as stratification variables in DLB clinical trials. TRIAL REGISTRATION INFORMATION: NCT04001517 at ClinicalTrials.gov.
引用
- Alam JJ, Maruff P, Doctrow SR, et al. Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies. Neurology. 2023. PMID: 37657939. doi:10.1212/WNL.0000000000207755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。